Dynavax Technologies
- Company typePublic
- Founded1997
- HeadquartersBerkeley, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Dynavax Technologies firmographics
Firmographics- Name
- Dynavax Technologies
- Legal name
- Dynavax Technologies Corporation
- Website
- https://dynavax.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Dynavax Technologies industry classification
Industry- Product category
- Vaccines
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)
- akta.pro secondary industries
- Vaccine Adjuvants & Formulation Systems (HLAIAEAI), Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD)
Keywords
Where Dynavax Technologies is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Dynavax Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- HEPLISAV-B Vaccine Sales: Dynavax generates revenue primarily from sales of its FDA-approved hepatitis B vaccine HEPLISAV-B. The vaccine generated $268 million in 2024 sales, representing 26% year-over-year growth. Q3 2025 revenue was $94.9 million, up 18% year-over-year.
- Partnership and Licensing Revenue: Dynavax receives upfront payments, equity investments, and potential milestone payments from partnerships. The Vaxart partnership provided $25 million upfront plus $5 million equity investment with up to $700 million in total potential milestones, royalties, and fees.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Dynavax Technologies product offering
Product offeringCore offering
Dynavax develops, manufactures, and commercializes novel vaccines against infectious diseases built around its proprietary CpG 1018 toll-like receptor 9 (TLR9) agonist adjuvant. Its flagship commercial product is HEPLISAV-B, an FDA-approved two-dose adult hepatitis B vaccine administered over one month, with a pipeline including the Z-1018 investigational shingles vaccine candidate in Phase 1/2 trials.
Product overview
Dynavax Technologies is a commercial-stage biopharmaceutical company that develops and commercializes novel vaccines to protect against infectious diseases. The company's portfolio centers on its proprietary CpG 1018® adjuvant technology, which is contained in its FDA-approved hepatitis B vaccine HEPLISAV-B® (launched Q1 2018 in the US, Q2 2022 in the EU). The pipeline includes Z-1018, a shingles vaccine candidate in Phase 1/2 trials, and various other vaccine programs. Dynavax was acquired by Sanofi in February 2026.
Differentiator
Problem solved
Functional benefit
Brands
- HEPLISAV-B: FDA-approved adult hepatitis B vaccine using CpG 1018 adjuvant technology.
- CpG 1018
Products and services
- HEPLISAV-B HEPLISAV-B is an FDA-approved adult hepatitis B vaccine that uses Dynavax's proprietary CpG 1018 adjuvant and is delivered as a two-dose regimen (one month apart) for adults 18 years and older, including those with chronic kidney disease and type 2 diabetes mellitus.
- CpG 1018 Adjuvant CpG 1018 is Dynavax's proprietary toll-like receptor 9 (TLR9) agonist adjuvant contained in HEPLISAV-B. It is licensed to biopharmaceutical partners for use in their vaccine candidates in exchange for upfront payments, equity investments, milestone payments, royalties, and fees.
Quantifiable outcome
- 26% year-over-year revenue growth for HEPLISAV-B in 2024, reaching $268 million in sales.
- +1 more outcomes
Companies that use Dynavax Technologies
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Dynavax Technologies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Dynavax Technologies partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- SanoficoreSanofi completed its acquisition of Dynavax Technologies on February 10, 2026, for approximately $2.2 billion ($15.50 per share). The acquisition brings Sanofi's adult hepatitis B vaccine HEPLISAV-B and the Z-1018 shingles vaccine candidate (in Phase 1/2). Dynavax became an indirect wholly owned subsidiary of Sanofi, with its shares delisted from Nasdaq.
- VaxartcoreDynavax entered an exclusive worldwide license and collaboration agreement with Vaxart in November 2025 to develop and commercialize Vaxart's oral COVID-19 vaccine candidate. Dynavax paid $25 million upfront plus a $5 million equity investment, with up to $700 million in potential milestones, royalties, and fees. Vaxart continues leading development through Phase 2b, after which Dynavax may assume late-stage development and commercialization.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Dynavax Technologies competitors and assessment
Company assessmentBroad incumbents
- Merck & Co. Large vaccine and biologics manufacturer with a portfolio that historically included Recombivax HB for hepatitis B. Highly comparable in commercial-stage vaccine distribution to healthcare providers, biopharmaceutical R&D scale, and infectious disease focus.
- GSK: Global biopharmaceutical company with a large vaccines franchise, including Shingrix (the direct competitor to Dynavax's Z-1018 shingles candidate) and prior hepatitis B vaccines. Comparable because of overlapping vaccine categories, immune-adjuvant research, and primary-care provider relationships that drive adult vaccine adoption.
- Sanofi Pasteur: Sanofi's vaccines division and now the parent organization of Dynavax following the February 2026 acquisition. Highly comparable in adult vaccine commercialization, hepatitis B franchise, and adjuvant technology development across the broader Sanofi vaccine portfolio.
Direct peers
- BioNTech: Commercial-stage vaccine company with an mRNA-based platform, originally commercialized through its COVID-19 partnership with Pfizer and now expanding into infectious disease and oncology vaccines. Comparable as a platform vaccine company leveraging novel immunological technology to develop infectious disease products.
- Novavax: Vaccine developer using proprietary Matrix-M adjuvant technology to enhance immune responses in protein-based vaccines. Comparable because of a similarly adjuvant-driven platform approach, focus on infectious disease vaccines, and commercial-stage status with established supply and distribution partnerships.
- Valneva: Specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases, including chikungunya, Lyme disease, and travel vaccines. Comparable as a commercial-stage vaccine developer with a focused infectious disease pipeline targeting adult and travel populations.
- Emergent BioSolutions: Biopharmaceutical company developing vaccines and therapeutics for infectious diseases and public health threats, with a portfolio that includes travel and routine vaccines. Comparable as a mid-cap commercial vaccine company with comparable R&D and manufacturing capabilities targeting infectious disease prevention.
- VBI Vaccines: Vaccine developer with approved hepatitis B vaccine (PreHevbrio/Sci-B-Vac) targeting adult and dialysis populations, directly overlapping with HEPLISAV-B's positioning. Comparable as a hepatitis B vaccine competitor with a similar adult-vaccination commercial focus.
- Moderna: mRNA vaccine platform company with approved COVID-19 and RSV vaccines and a broad infectious disease pipeline. Comparable as a commercial-stage vaccine developer with platform-based technology, focused on infectious disease prevention in adult populations.
Emerging players
- Inovio Pharmaceuticals: Clinical-stage vaccine developer using a DNA-based platform to target infectious diseases and cancer. Comparable as a smaller platform-vaccine company focused on novel immune-activation approaches for infectious disease indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Dynavax Technologies social profiles
Digital presenceDynavax Technologies compliance and trust
Trust signalCompliance6 records
Dynavax Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dynavax Technologies leadership team
Management profileNumber of profiles
Profiles6 records
Dynavax Technologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
Dynavax Technologies funding detail
Funding detailFunding overview
Funding rounds19 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dynavax Technologies M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dynavax Technologies
What does Dynavax Technologies do?
Dynavax develops, manufactures, and commercializes novel vaccines against infectious diseases built around its proprietary CpG 1018 toll-like receptor 9 (TLR9) agonist adjuvant. Its flagship commercial product is HEPLISAV-B, an FDA-approved two-dose adult hepatitis B vaccine administered over one month, with a pipeline including the Z-1018 investigational shingles vaccine candidate in Phase 1/2 trials.
Is Dynavax Technologies a public or private company?
Dynavax Technologies is a public company. It is classified as corporate owned and is currently acquired.
When was Dynavax Technologies founded?
Dynavax Technologies was founded in 1997. It employs 251 to 500 people.
Where is Dynavax Technologies based?
Dynavax Technologies is headquartered in Berkeley, United States, in the North America region.
How does Dynavax Technologies make money?
Two revenue lines are on record. HEPLISAV-B Vaccine Sales are the primary driver. The others are partnership and Licensing Revenue.
Who are Dynavax Technologies's main competitors?
Broad incumbents on record are Merck & Co., GSK and Sanofi Pasteur. Direct peers are BioNTech, Novavax, Valneva, Emergent BioSolutions, VBI Vaccines and Moderna. Inovio Pharmaceuticals is listed as an emerging player.
Does Dynavax Technologies have an API?
No public API is recorded for Dynavax Technologies.
What industry is Dynavax Technologies in?
Dynavax Technologies's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAIAEAI, Vaccine Adjuvants & Formulation Systems. Its SIC code is 2836.